These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Structural constraints imposed by the conserved fusion peptide on the HIV-1 gp41 epitope recognized by the broadly neutralizing antibody 2F5. de la Arada I; Julien JP; de la Torre BG; Huarte N; Andreu D; Pai EF; Arrondo JL; Nieva JL J Phys Chem B; 2009 Oct; 113(41):13626-37. PubMed ID: 19754136 [TBL] [Abstract][Full Text] [Related]
7. A monomeric 3(10)-helix is formed in water by a 13-residue peptide representing the neutralizing determinant of HIV-1 on gp41. Biron Z; Khare S; Samson AO; Hayek Y; Naider F; Anglister J Biochemistry; 2002 Oct; 41(42):12687-96. PubMed ID: 12379111 [TBL] [Abstract][Full Text] [Related]
8. Enhancement of alpha -helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro. Implications for vaccine design. Joyce JG; Hurni WM; Bogusky MJ; Garsky VM; Liang X; Citron MP; Danzeisen RC; Miller MD; Shiver JW; Keller PM J Biol Chem; 2002 Nov; 277(48):45811-20. PubMed ID: 12237296 [TBL] [Abstract][Full Text] [Related]
9. HIV-1 membrane fusion mechanism: structural studies of the interactions between biologically-active peptides from gp41. Lawless MK; Barney S; Guthrie KI; Bucy TB; Petteway SR; Merutka G Biochemistry; 1996 Oct; 35(42):13697-708. PubMed ID: 8885850 [TBL] [Abstract][Full Text] [Related]
10. Human immunodeficiency virus type 1-neutralizing monoclonal antibody 2F5 is multispecific for sequences flanking the DKW core epitope. Menendez A; Chow KC; Pan OC; Scott JK J Mol Biol; 2004 Apr; 338(2):311-27. PubMed ID: 15066434 [TBL] [Abstract][Full Text] [Related]
11. Structure-affinity relationships in the gp41 ELDKWA epitope for the HIV-1 neutralizing monoclonal antibody 2F5: effects of side-chain and backbone modifications and conformational constraints. Tian Y; Ramesh CV; Ma X; Naqvi S; Patel T; Cenizal T; Tiscione M; Diaz K; Crea T; Arnold E; Arnold GF; Taylor JW J Pept Res; 2002 Jun; 59(6):264-76. PubMed ID: 12010517 [TBL] [Abstract][Full Text] [Related]
12. HIV-1 vaccine development: constrained peptide immunogens show improved binding to the anti-HIV-1 gp41 MAb. McGaughey GB; Citron M; Danzeisen RC; Freidinger RM; Garsky VM; Hurni WM; Joyce JG; Liang X; Miller M; Shiver J; Bogusky MJ Biochemistry; 2003 Mar; 42(11):3214-23. PubMed ID: 12641452 [TBL] [Abstract][Full Text] [Related]
13. Mode of interaction between the HIV-1-neutralizing monoclonal antibody 2F5 and its epitope. Fiebig U; Schmolke M; Eschricht M; Kurth R; Denner J AIDS; 2009 May; 23(8):887-95. PubMed ID: 19414989 [TBL] [Abstract][Full Text] [Related]
14. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Cardoso RM; Zwick MB; Stanfield RL; Kunert R; Binley JM; Katinger H; Burton DR; Wilson IA Immunity; 2005 Feb; 22(2):163-73. PubMed ID: 15723805 [TBL] [Abstract][Full Text] [Related]
15. Conformational study of fragments of envelope proteins (gp120: 254-274 and gp41: 519-541) of HIV-1 by NMR and MD simulations. Kanyalkar M; Srivastava S; Saran A; Coutinho E J Pept Sci; 2004 Jun; 10(6):363-80. PubMed ID: 15214441 [TBL] [Abstract][Full Text] [Related]
16. The gp41(659-671) HIV-1 antibody epitope: a structurally challenging small peptide. Zhang Y; Sagui C J Phys Chem B; 2014 Jan; 118(1):69-80. PubMed ID: 24359409 [TBL] [Abstract][Full Text] [Related]
17. Peptide P5 (residues 628-683), comprising the entire membrane proximal region of HIV-1 gp41 and its calcium-binding site, is a potent inhibitor of HIV-1 infection. Yu H; Tudor D; Alfsen A; Labrosse B; Clavel F; Bomsel M Retrovirology; 2008 Oct; 5():93. PubMed ID: 18925934 [TBL] [Abstract][Full Text] [Related]
18. Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection. Bianchi E; Finotto M; Ingallinella P; Hrin R; Carella AV; Hou XS; Schleif WA; Miller MD; Geleziunas R; Pessi A Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12903-8. PubMed ID: 16129831 [TBL] [Abstract][Full Text] [Related]
19. Differential inhibition of HIV-1 and SIV envelope-mediated cell fusion by C34 peptides derived from the C-terminal heptad repeat of gp41 from diverse strains of HIV-1, HIV-2, and SIV. Gustchina E; Hummer G; Bewley CA; Clore GM J Med Chem; 2005 Apr; 48(8):3036-44. PubMed ID: 15828842 [TBL] [Abstract][Full Text] [Related]
20. T-20 and T-1249 HIV fusion inhibitors' structure and conformation in solution: a molecular dynamics study. Martins Do Canto AM; Palace Carvalho AJ; Prates Ramalho JP; Loura LM J Pept Sci; 2008 Apr; 14(4):442-7. PubMed ID: 18069719 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]